Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by BTIG Research to Buy Rating
BTIG Research upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) from a neutral rating to a buy rating in a research report released on Tuesday morning, Marketbeat.com reports. They currently have $8.00 target price on the biotechnology company’s stock. ACRS has been the subject of several other research reports. Piper Sandler raised shares of […]
More Stories
StockNews.com Initiates Coverage on Stericycle (NASDAQ:SRCL)
StockNews.com assumed coverage on shares of Stericycle (NASDAQ:SRCL – Free Report) in a research note issued to investors on Wednesday....
Freedom Holding Corp. (NASDAQ:FRHC) Insider Sells $876,346.92 in Stock
Freedom Holding Corp. (NASDAQ:FRHC – Get Free Report) insider Azamat Yerdessov sold 7,521 shares of the firm’s stock in a...
Insider Selling: The Honest Company, Inc. (NASDAQ:HNST) General Counsel Sells 107,653 Shares of Stock
The Honest Company, Inc. (NASDAQ:HNST – Get Free Report) General Counsel Brendan Sheehey sold 107,653 shares of Honest stock in...
Donegal Group Inc. (NASDAQ:DGICA) Major Shareholder Buys $596,795.88 in Stock
Donegal Group Inc. (NASDAQ:DGICA – Get Free Report) major shareholder Mutual Insurance Co Donegal purchased 37,748 shares of Donegal Group...
Landscape Capital Management L.L.C. Sells 335,017 Shares of Sally Beauty Holdings, Inc. (NYSE:SBH)
Landscape Capital Management L.L.C. lessened its holdings in shares of Sally Beauty Holdings, Inc. (NYSE:SBH – Free Report) by 82.9%...
Landscape Capital Management L.L.C. Reduces Position in Credit Acceptance Co. (NASDAQ:CACC)
Landscape Capital Management L.L.C. reduced its holdings in Credit Acceptance Co. (NASDAQ:CACC – Free Report) by 34.3% during the 3rd...